Johnson & Johnson announces submission of application to the U.S. FDA for Emergency Use Authorization of its investigational single-shot Janssen COVID-19 vaccine candidate

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news